Seletracetam (Ucb 44212) is an analog of the antiepileptic agent Levetiracetam. Seletracetam is a small molecule SV2A modulator for the research of epilepsy[1][2][3].

**IC₅₀ & Target**  
SV2A[1]

**In Vitro**  
Seletracetam decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A[2].

Seletracetam decreases synaptic responses in a time-, frequency- and concentration-dependent manner[2].

Seletracetam modifies rates of presynaptic release[2].

Seletracetam inhibits high-voltage-activated Ca²⁺ currents and intracellular Ca²⁺ increase in rat cortical neurons in vitro[2].

**REFERENCES**

